Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT03710876
Title Efficacy & Safety of rAd-IFN Administered With Celecoxib & Gemcitabine in Patients With Malignant Pleural Mesothelioma (INFINITE)
Acronym INFINITE
Recruitment Active, not recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors Trizell Ltd
Indications
Therapies
Age Groups: senior | adult
Covered Countries USA | POL | ITA | GBR | FRA | DEU | CAN | AUS


No variant requirements are available.